Status In progress
Process STA 2018
ID number 1188

Provisional Schedule

Appraisal consultation: 1 10 January 2019 - 31 January 2019

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews


Companies sponsors Novartis (erenumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Migraine Trust
Professional groups Association of British Neurologists
  British Association for the Study of Headache
  Primary Care Neurology Society
  Royal College of Physicians
  UK Clinical Pharmacy Association


Comparator companies Allergan (botulinum toxin type A)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups National Hospital for Neurology and Neurosurgery


Key events during the development of the guidance:

Date Update
06 December 2018 Committee meeting: 1
18 July 2018 Following an update from the company, this appraisal has been rescheduled. We anticipate that the appraisal will continue later in 2018 and will provide a further update on the timings when more information is available.
01 March 2018 Invitation to participate
22 February 2018 In progress, Referral received 05.12.17 so webpage amended
05 December 2017 Referral
25 May 2017 - 23 June 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance